Q32 Bio Q3 net loss rises to $8.9 million; bempikibart Part B data presented
Q32 Bio reported a third-quarter 2026 net loss of $8.9 million, or $0.26 per share, compared with $7.4 million, or $0.60 per share, a year earlier. The loss grew while per-share loss narrowed, as weighted-average shares rose to about 34.0 million from 12.2 million. The company also presented additional SIGNAL-AA Part B results and said it expects to start a registration-directed program in the first half of 2027, subject to regulatory discussions in the fourth quarter of 2026.
Key points
- Net loss was $8.9 million for the quarter ended September 30, 2026, versus $7.4 million a year earlier.
- Net loss per share was $0.26 versus $0.60, with weighted-average shares of 34,022,755 versus 12,240,542.
- Cash and cash equivalents were $289.6 million at September 30, 2026, versus $48.3 million at December 31, 2025.
- Research and development expenses were $5.1 million, up from $3.6 million, and general and administrative expenses were $5.5 million, up from $4.0 million.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.